As of 2026-06-14, the EV/EBITDA ratio of Ose Immunotherapeutics SA (OSE.PA) is -2.12. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. OSE.PA's latest enterprise value is 101.50 mil EUR. OSE.PA's TTM EBITDA according to its financial statements is -47.78 mil EUR. Dividing these 2 quantities gives us the above OSE.PA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 3.8x - 6.4x | 5.2x |
| Forward P/E multiples | 6.7x - 14.5x | 8.3x |
| Fair Price | (14.70) - (14.07) | (14.81) |
| Upside | -477.9% - -461.6% | -480.6% |
| Date | EV/EBITDA |
| 2026-06-12 | -2.12 |
| 2026-06-11 | -2.36 |
| 2026-06-10 | -1.92 |
| 2026-06-09 | -1.93 |
| 2026-06-08 | -1.96 |
| 2026-06-05 | -2.03 |
| 2026-06-04 | -2.03 |
| 2026-06-03 | -2.03 |
| 2026-06-02 | -2.09 |
| 2026-06-01 | -2.26 |
| 2026-05-29 | -2.36 |
| 2026-05-28 | -2.54 |
| 2026-05-27 | -2.51 |
| 2026-05-26 | -2.61 |
| 2026-05-25 | -2.76 |
| 2026-05-22 | -2.78 |
| 2026-05-21 | -2.63 |
| 2026-05-20 | -2.61 |
| 2026-05-19 | -2.63 |
| 2026-05-18 | -2.72 |
| 2026-05-15 | -2.85 |
| 2026-05-14 | -2.62 |
| 2026-05-13 | -2.59 |
| 2026-05-12 | -2.33 |
| 2026-05-11 | -2.38 |
| 2026-05-08 | -2.11 |
| 2026-05-07 | -2.15 |
| 2026-05-06 | -2.22 |
| 2026-05-05 | -1.99 |
| 2026-05-04 | -2.01 |
| 2026-04-30 | -2.09 |
| 2026-04-29 | -2.15 |
| 2026-04-28 | -2.30 |
| 2026-04-27 | -2.01 |
| 2026-04-24 | -1.71 |
| 2026-04-23 | -1.74 |
| 2026-04-22 | -1.72 |
| 2026-04-21 | -1.76 |
| 2026-04-20 | -1.81 |
| 2026-04-17 | -1.86 |
| 2026-04-16 | -1.83 |
| 2026-04-15 | -1.79 |
| 2026-04-14 | -1.82 |
| 2026-04-13 | -1.77 |
| 2026-04-10 | -1.76 |
| 2026-04-09 | -1.77 |
| 2026-04-08 | -1.84 |
| 2026-04-07 | -1.73 |
| 2026-04-02 | -1.84 |
| 2026-04-01 | -1.83 |